Final Prospectus Filed for Resale of 13.8M Shares by Selling Stockholders
VOR has more than doubled off its 52-week low of $2.622.
Summary
Vor Biopharma filed a final prospectus enabling selling stockholders to resell 13.8 million shares, representing a substantial portion of the company's market capitalization, with no proceeds going to the company.
Key Events · Financing and Capital Events · VOR
-
Resale of Shares Registered
A final prospectus was filed for the resale of 13,876,032 shares of common stock by selling stockholders, making these shares available for sale on the open market.
-
No Proceeds to Company
Vor Biopharma will not receive any funds from the sale of these shares, as the transaction is solely for the benefit of the selling stockholders.
-
Significant Market Overhang
The 13.8 million shares available for resale represent a substantial portion of the company's market capitalization, potentially creating downward pressure on the stock price due to increased supply.
-
Follows Prior Private Placement
These shares originated from a private placement on December 18, 2025, where the company raised $150 million by issuing shares at $10.81 each.
Analysis · VOR · Life Sciences
This 424B3 filing finalizes the registration for the resale of 13.8 million shares of common stock by existing stockholders, following the S-3 registration statement filed on January 29, 2026. These shares were originally issued in a private placement on December 18, 2025, at $10.81 per share, generating $150 million for the company. However, the company will not receive any proceeds from the current resale by selling stockholders. The availability of such a large block of shares, representing approximately 63% of the current market capitalization, creates a significant overhang on the stock, potentially exerting downward pressure on its price as investors may anticipate increased supply.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 35.6% of the 1805 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, VOR was trading at $12.07 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $264.5M. The 52-week trading range was $2.62 to $65.80. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.